G. Garibaldi

发表

Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data

S. Kapur, J. Rabinowitz, S. Levine, 2012, Schizophrenia Research.

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.

M. Ostland, D. Umbricht, G. Garibaldi, 2014, JAMA psychiatry.

Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms

S. Marder, G. Garibaldi, D. Bugarski-Kirola, 2014, Psychiatry Research.

Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial p

S. Kapur, G. Garibaldi, D. Bugarski-Kirola, 2016, The lancet. Psychiatry.

Bitopertin in Negative Symptoms of Schizophrenia—Results From the Phase III FlashLyte and DayLyte Studies

S. Lawrie, S. Marder, W. Fleischhacker, 2017, Biological Psychiatry.

Defining therapeutic benefit for people with schizophrenia: Focus on negative symptoms

S. Potkin, R. Buchanan, S. Leucht, 2015, Schizophrenia Research.

PMH56 Negative Symptoms Have Greater Impact on Functioning Than Positive Symptoms in Schizophrenia: Analysis of Catie Data

S. Kapur, J. Rabinowitz, S. Levine, 2011 .

Psychometric evaluation of the Work Readiness Questionnaire in schizophrenia

S. Potkin, G. Garibaldi, D. Bugarski-Kirola, 2014, CNS Spectrums.

Psychometric evaluation of a Patient-Rated Most Troubling Symptom Scale for Depression: findings from a secondary analysis of a clinical trial

D. Revicki, G. Garibaldi, L. Kleinman, 2010, International clinical psychopharmacology.

Apathy in Neurodegenerative Diseases: Recommendations on the Design of Clinical Trials

J. Cummings, P. Robert, J. Friedman, 2015 .

Quantifying motivational deficits and apathy: A review of the literature

G. Garibaldi, M. Weiser, 2015, European Neuropsychopharmacology.

Apathy in Neurodegenerative Diseases

J. Cummings, P. Robert, J. Friedman, 2015, Journal of geriatric psychiatry and neurology.

Pharmacological approaches to treating negative symptoms: A review of clinical trials

S. Marder, C. Arango, G. Garibaldi, 2013, Schizophrenia Research.

A Randomized, Placebo-Controlled Study Investigating the Nicotinic α7 Agonist, RG3487, for Cognitive Deficits in Schizophrenia

D. Umbricht, G. Garibaldi, R. Keefe, 2014, Neuropsychopharmacology.

Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia

Michael F. Green, Philip D. Harvey, A. Malhotra, 2013, Schizophrenia Research.

Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders.

J. Calabrese, M. Fava, A. Nierenberg, 2014, Journal of affective disorders.

Efficacy and safety of adjunctive bitopertin (5 and 10mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics — Results from the phase III DayLyte study

S. Lawrie, C. Arango, G. Garibaldi, 2014, Schizophrenia Research.

Bitopertin in Negative Symptoms of Schizophrenia—Results From the Phase III FlashLyte and DayLyte Studies

S. Lawrie, S. Marder, W. Fleischhacker, 2017, Biological Psychiatry.

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.

M. Ostland, D. Umbricht, G. Garibaldi, 2014, JAMA psychiatry.